Enlivex

ENLV · NASDAQ

$0.2237+$0.0163 (+7.86%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $0.2074

About ENLV

Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. The company is headquartered in Ness Ziona, Central(Hamerkaz) and currently employs 34 full-time employees. The company went IPO on 2014-07-30. The firm focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID‑19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand‑alone therapy or in combination with other treatments.

Employees: 34
Headquarters: Ness Ziona, Central(HaMerkaz)
Listed: Jul 30, 2014
Sector: Health Care
Industry: Biotechnology
Website: enlivex.com

Leadership

Enlivex executives
Name	Title	Since	Age
Shai Novik	—	2014	59
Oren Hershkovitz	—	—	44
Prof. Dror Mevorach	—	—	65
Shachar Shlosberger	—	—	44
Baruch Halpert	—	—	54
Bernhard Kirschbaum	—	—	64
Sangwoo Lee	—	—	—
Matteo Renzi	—	—	—
Brian Schwartz	—	—	61
Michel Habib	—	—	58
Gili Hart	—	—	46
Abraham Havron	—	—	73

Similar companies

Companies in the same industry as Enlivex

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.